Immunogenicity, safety and tolerability of meningococcal C CRM197 conjugate vaccine administered 3, 5 and 11 months post-natally to pre- and full-term infants

Vaccine

Volumn 25, Issue 26, 2007, Pages 4889-4894

  Esposito, Susanna ^a   Corbellini, Barbara ^b   Bosis, Samantha ^a   Pugni, Lorenza ^a   Tremolati, Elena ^a   Tagliabue, Claudia ^a   Toneatto, Daniela ^b   Mosca, Fabio ^a   Principi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Meningococcal C conjugate vaccine; Neisseria meningitidis; Pre term infants

Indexed keywords

MENINGOCOCCUS VACCINE;

ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE SWELLING; IRRITABILITY; MENINGOCOCCOSIS; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; VACCINATION;

AGING; ANTIBODIES, BACTERIAL; COST CONTROL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; MENINGOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 34249784520     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.018     Document Type: Article

References (30)

1. Pollard A.J. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 23 (2004) S274-S279
2. Baltimore R.S. Recent trends in meningococcal epidemiology and current vaccine recommendations. Curr Opin Pediatr 18 (2006) 58-63
3. Trotter C.L., Gay N.J., and Edmunds W.J. The natural history of meningococcal carriage and disease. Epidemiol Infect 134 (2006) 556-566
4. Kaplan S.L., Schutze G.E., Leake J.A., Barson W.J., Halasa N.B., Byington C.L., et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 118 (2006) e979-e984
5. Sharip A., Sorvillo F., Redelings M.D., Mascola L., Wise M., and Nguyen D.M. Population-based analysis of meningococcal disease mortality in the United States: 1990-2002. Pediatr Infect Dis J 25 (2006) 191-194
6. Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med 355 (2006) 1466-1473
7. Conterno L.O., Silva Filho C.R., Rüggeberg J.U., and Heath P.T. Conjugate vaccines for preventing meningococcal C meningitis and septicaemia. Cochrane Database Syst Rev 3 (2006) CD001834
8. Richmond P., Borrow R., Miller F., Clark S., Sadler F., Fox A., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179 (1999) 1569-1572
9. MacLennan J., Shackley F., Heath P.T., Deeks J.J., Flamank C., Herbert M., et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants. A randomized controlled trial. JAMA 283 (2000) 2795-2801
10. Slack M.H., Schapira D., Thwaites R.J., Burrage M., Southern J., Andrews N., et al. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. J Infect Dis 184 (2001) 1617-1620
11. Bramley J.C., Hall T., Finn A., Buttery R.B., Elliman D., Lockhart S., et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine 19 (2001) 2924-2931
12. Borrow R., Goldblatt D., Andrews N., Southern J., Ashton L., Deane S., et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J infect Dis 186 (2002) 1353-1357
13. Borrow R., Glodblatt D., Finn A., Southern J., Ashton L., Andrews N., et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect Immun 71 (2003) 5549-5555
14. Tejedor J.C., Omenaca F., Garcia-Sicilia J., Verdaguer J., Van Esso D., Esporrin C., et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J 23 (2004) 1109-1115
15. Slack M.H., Cade S., Schapira D., Thwaites R.J., Crowley-Luke A., Southern J., et al. DT5aP-Hib-IPV and MCC vaccines: preterm infants' response to accelerated immunisation. Arch Dis Child 90 (2005) 338-341
16. Collins C.L., Ruggeberg J.U., Balfour G., Tighe H., Archer M., Bowen-Morris J., et al. Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infants. Pediatr Infect Dis J 24 (2005) 966-968
17. Kitchin N., Southern J., Morris R., Hemme F., Cartwright K., Watson M., et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine 24 (2006) 3964-3970
18. Tejedor J.C., Moro M., Ruiz-Contreras J., Castro J., Gómez-Campderà J.A., Navarro M.L., et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 25 (2006) 713-720
19. Miller E., Salisbury D., and Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 Suppl. 1 (2001) S58-S67
20. Esposito S., Pugni L., Bosis S., Proto A., Cesati L., Bianchi C., et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 23 (2005) 1703-1708
21. Trotter C., Andrews N., Kaczmarski E., Miller E., and Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 (2004) 365-367
22. de Wals P., Trottier P., and Pépin J. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine 24 (2006) 3500-3504
23. Richmond P., Borrow R., Findlow J., Martin S., Thornton C., Cartwright K., et al. Evaluation of De-O-acetyled meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup O strains. Infect Immun 69 (2001) 2378-2382
24. McVernon J., Mitchison N.A., and Moxon E.R. T helper cells and efficacy of Haemophilus influenzae type b conjugate vaccination. Lancet Infect Dis 4 (2004) 40-43
25. Ladhani S., Slack M.P., Heath P.T., and Ramsay M.E. Changes in ascertainment of Hib and its influence on the estimation of disease incidence in the United Kingdom. Epidemiol Infect 9 November (2006) 1-7
26. Borrow R., Andrews N., Goldblatt D., and Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 69 (2001) 1568-1573
27. Borrow R., Balmer P., and Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 23 (2005) 2222-2227
28. Slack M.H., Schapira C., Thwaites R.J., Andrews N., and Schapira D. Acellular pertussis and meningococcal C vaccines: cardio-respiratory events in preterm infants. Eur J Pediatr 162 (2003) 436-437
29. Slack M.H., and Schapira D. Severe apnoeas following immunisation in premature infants. Arch Dis Child Fetal Neonatal Ed 81 (1999) F67-F68
30. Shepard C.W., Ortega-Sanchez I.R., Scott II R.D., Rosenstein N.E., and ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 115 (2005) 1220-1232